Op-Ed: The best way to capitalize on the potential revenue influx from enterprise-level drug adherence programs is to create room at the executive table for a Chief Adherence Officer.
Tom Kottler
Advertisement
Tom Kottler is co-founder and Chief Executive Officer of HealthPrize Technologies, the leading digital adherence and patient engagement platform for life science companies. Kottler has led multiple high-growth organizations during his career, including Advanced BioHealing, which was acquired by Shire for $750 million, and MedAptus, an innovative healthcare IT company based in Boston, Mass.
Articles by Tom Kottler
Outside of raising prices, pharma can generate new revenue from just three other sources, write Tom Kottler.
Addressing adherence with c-suite sponsorship and at scale has the capacity increase revenue, improve patient outcomes and lower health care costs, writes Tom Kottler.
Advertisement
Latest Updated Articles
Adherence: Addressing Pharma's Last-Mile ProblemPublished: June 5th 2018 | Updated:
- Time is Running Out for Pharma to Change Course
Published: April 1st 2019 | Updated:
It’s Time for a Chief Adherence OfficerPublished: May 8th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Alkermes plc Acquiring Avadel Pharmaceuticals in $2.1 Billion Definitive Agreement
2
Pharmaceutical Executive Daily: Novo Nordisk's Shares Fall After Board Shake-Up
3
Novo Nordisk Stock Reacts to Recent Board Changes
4
What Impact will DTC Programs Have on Prescription Drug Prices?
5
